Abstract

Abstract:
The review clarifies key findings by providing a thorough assessment of lymphedema, hyperbaric oxygen therapy (HBOT), and quality of life (QOL) following breast cancer. Lymphedema is a common side effect of breast cancer treatment that lowers quality of life. HBOT shows promise as a post-treatment intervention for lymphedema from breast cancer, particularly when used in conjunction with more established treatments such as complex decongestive therapy (CDT). Furthermore, HBOT significantly improves quality of life (QOL) for a wide range of acute and chronic diseases, including cancer therapies like radiation for early- stage breast cancer. Important information is provided by clinical trials examining the potential of HBOT to reduce lymphedema symptoms following breast cancer therapy. However, more research using bigger sample numbers and regulated procedures is required to determine the precise efficacy and cost- effectiveness of HBOT. Furthermore, promising outcomes of HBOT on arm lymphedema following adjuvant radiation therapy for early-stage breast cancer were reported by Lone Gothard et al., indicating the need for additional randomised trials. The prospective therapeutic benefits of HBOT in this population are highlighted by Marilot C. T. Batenburg et al.'s cohort research, which shows significant reductions in pain, arm and breast symptoms, and quality of life (QOL) following HBOT in breast cancer patients with late radiation damage.

Key words: Breast Cancer, Hyperbaric Oxygen, improve Quality of life,Lymphedema